Summary
Boston Scientific Corporation (BSX) announced on March 30, 2017, the signing of a definitive agreement to acquire Symetis SA. This strategic move is expected to be completed in the second quarter of 2017, subject to customary closing conditions. The acquisition of Symetis SA, a company not further detailed in this specific filing, is presented as a material event and is accompanied by a press release that provides additional information. Investors should note that this filing is primarily an "Other Events" disclosure, focusing on the agreement to acquire. While financial details of the Symetis acquisition are not provided in this 8-K, the forward-looking statements included highlight the company's expectations for this transaction and acknowledge potential risks and uncertainties that could impact the actual outcome. BSX has also incorporated by reference risks disclosed in its most recent Form 10-K and subsequent 10-Q filings, underscoring the importance of reviewing those documents for a comprehensive understanding of potential impacts.
Key Highlights
- 1Boston Scientific Corporation (BSX) has signed a definitive agreement to acquire Symetis SA.
- 2The acquisition is anticipated to close in the second quarter of 2017.
- 3Completion of the acquisition is subject to customary closing conditions.
- 4This event is disclosed under Item 8.01 (Other Events) of the 8-K filing.
- 5A press release detailing the acquisition agreement is filed as Exhibit 99.1.
- 6The filing includes forward-looking statements regarding the expected completion of the acquisition.
- 7BSX cautions investors about potential risks and uncertainties that could affect the acquisition's completion or future results.